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Abstract
High-grade dysplasia carries significant risk of transformation to hepatocellular carcinoma (HCC). Despite this, at the
current standard of care, all non-malignant hepatic nodules including high-grade dysplastic nodules are managed sim-
ilarly. This is partly related to difficulties in distinguishing high-risk pathology in the liver. We aimed to identify chro-
mosome arm-level somatic copy number alterations (SCNAs) that characterise the transition of liver nodules along the
cirrhosis–dysplasia–carcinoma axis. We validated our findings on an independent cohort using blood-derived cell-free
DNA. A repository of non-cancer DNA sequences obtained from patients with HCC (n = 389) was analysed to generate
cut-off thresholds aiming tominimise false-positive SCNAs. Tissue samples representing stages from themultistep pro-
cess of hepatocarcinogenesis (n = 184) were subjected to low-pass whole genome sequencing. Chromosome arm-level
SCNAswere identified in liver cirrhosis, dysplastic nodules, and HCC to assess their discriminative capacity. Samples pos-
itive for 1q+ or 8q+ arm-level duplications were likely to be either HCC or high-grade dysplastic nodules as opposed to
low-grade dysplastic nodules or cirrhotic tissue with an odds ratio (OR) of 35.5 (95% CI 11.5–110) and 16 (95% CI
6.4–40.2), respectively (p < 0.0001). In an independent cohort of patients recruited from Nottingham, UK, at least
two out of four alterations (1q+, 4q, 8p, and 8q+) were detectable in blood-derived cell-free DNA of patients with
HCC (n = 22) but none of the control patients with liver cirrhosis (n = 9). Arm-level SCNAs on 1q+ or 8q+ are asso-
ciated with high-risk liver pathology. These can be detected using low-pass sequencing of cell-free DNA isolated from
blood, which may be a future early cancer screening tool for patients with liver cirrhosis.
©2021 TheAuthors. The Journal of Pathology published by JohnWiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain
and Ireland.
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Introduction
Early events in hepatocarcinogenesis involve the pro-
gression of dysplastic nodules (DNs) to overt hepatocel-
lular carcinoma (HCC). Such a contention has been
supported by the frequent appearance of nodule-in-
nodule lesions containing both dysplasia and cancer
[1]. In comparison to regenerative nodules, DNs have
an increased risk of malignant transformation [2]. Geno-
mic features common to hepatic dysplasia and
carcinoma demonstrate a step-wise increase in chromo-
some arm-level somatic copy number alterations
(SCNAs) [3,4], chromosomal instability [3,5], and
TERT promoter mutations [6,7]. Among dysplastic nod-
ules, a histological distinction can be drawn between
those that are ‘low-grade’ DNs and those that are
‘high-grade’. The latter are assumed to be the immediate
precursors of overt HCC. The rate of HCC development
was found to be significantly higher in high-grade DNs
than in low-grade DNs and regenerative nodules [8].
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Accurate histological diagnosis of cancer or nodules
that have a high likelihood of evolving into cancer is
required. Such diagnosis is currently based on morphol-
ogy, supplemented with immunohistochemistry where
available, but the diagnosis is subjective and remains
challenging in routine clinical practise [9]. The difficulty
in histological diagnosis is focused on differentiating
low-grade DNs from high-grade DNs and high-grade
DNs from histologically well-differentiated HCC and
there is a need for additional diagnostic tests which could
be applied to fixed tissue or blood samples. Previous
studies with focus on the prevalence of arm-level
SCNAs identified 1q+ and 8q+ as common events in
HCC [10], significantly less common in DNs [3,4], and
rare events in cirrhosis [11]. However, their discrimina-
tory role has not been investigated previously. We
aimed, therefore, to identify the utility of arm-level
SCNAs as an aid for stratifying high- and low-risk
pathology along the cirrhosis–dysplasia–carcinoma axis
using low-pass sequencing.
High-quality deep sequencing analysis of the HCC
genome has been conducted in various contexts and
has led to thorough characterisation of its main genomic
features [10,12–15]. However, costly and time-
consuming deep sequencing is not required for detection
of arm-level SCNAs. For several decades, conventional
karyotyping and chromosomal microarrays were stan-
dard [16]. More recently, low-pass next-generation
sequencing (NGS) was validated with as little as 5 ng
of DNA needed to generate a copy number karyogram
[17–19] and reports of higher accuracy with an average
coverage of 0.25x and mosaic levels as low as
20% [20].
Cell-free DNA refers to non-encapsulated DNA circu-
lating freely in the blood stream. In cancer patients, a
variable proportion of cell-free DNA originates from
tumour cells. HCC is known to possess relatively high
amplitude gains in copy number on 1q and 8q in compar-
ison to other parts of the genome [10,11]. Therefore,
both chromosomal arms offer natural signal amplifica-
tion, boosting detectability within the plasma pool of
cell-free DNA. Therefore, we tested the applicability




The Cancer Genome Atlas (TCGA; https://portal.gdc.
cancer.gov/) is a public repository which includes
high-quality genomic sequencing data from cancer tis-
sue as well as matched non-cancer tissue of patients with
cancer. We first downloaded all the ‘cancer’ and ‘non-
cancer’ copy number segment files of patients with liver
hepatocellular carcinoma (TCGA-LIHC) which were
used as the derivation cohort (Figure 1) [10]. We used
Figure 1. Description of study cohorts. (A) Derivation/TCGA cohort: TCGA-LIHC non-cancer sub-cohort (n = 389) was used to generate
thresholds above or below which copy number gains or losses were called in test samples, respectively. TCGA-LIHC cancer sub-cohort
(n = 379) was used to identify key arm-level SCNAs in HCC. The thresholds were validated for false positives against 7457 patients consti-
tuting the TCGA threshold validation sub-cohort, which is non-cancer tissue DNA of patients diagnosed with 26 different types of cancer but
not HCC. (B) Validation cohort 1 (formalin-fixed, paraffin-embedded) was used to validate the ability of key arm-level SCNAs identified from
the derivation cohort in classifying low- and high-risk liver pathology. (C) Validation cohort 2 (blood-derived cell-free DNA). The total number
of samples per cohort and the main clinical features of samples in each cohort are highlighted. HGDN, high-grade dysplastic nodules; LGDN,
low-grade dysplastic nodules; MDHCC, moderately differentiated HCC; PDHCC, poorly differentiated HCC; WDHCC, well-differentiated HCC.
2 W Fateen et al
© 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd.
on behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org
J Pathol 2021; 00: 000–000
www.thejournalofpathology.com
the TCGA-LIHC non-cancer sub-cohort to generate
thresholds above or below which copy number gains or
losses were called in cancer samples, respectively. Next,
we identified key arm-level SCNAs in the TCGA-LIHC
cancer sub-cohort. Using the first validation cohort, we
analysed the ability of key arm-level SCNAs to discrim-
inate between low- and high-risk pathology. Lastly, we
used the second validation cohort to test the principle
that low-pass sequencing of cell-free DNA from blood
samples offers a future early cancer screening tool for
patients with liver cirrhosis using liquid biopsies.
Ethical approval and sample collection
The study was approved by the UK National Research
Ethics Service (NRES, reference: 10/H1310/61) and
Ain Shams University Hospitals local research ethics
committee (LREC, reference: FMASU/485/2009).
Anonymised samples were obtained from the Notting-
ham Digestive Diseases Biomedical Research Unit Tis-
sue Bank (NRES, Ref 14/WA/1234). Tissue and blood
samples were collected from three hospitals: St James’s
University Hospital, Leeds (UK); Nottingham Univer-
sity Hospitals NHS Trust, Nottingham (UK); and Ain
Shams Specialised Hospital, Cairo (Egypt). Samples
used in this study were divided into two cohorts:
• Validation cohort 1 – formalin-fixed, paraffin-embed-
ded (FFPE) tissue from explanted liver specimens of
59 patients with HCC and/or dysplastic nodules com-
plicating cirrhosis due to hepatitis C (supplementary
material, Table S1 for clinico-pathological character-
istics and Table S2 for histopathology). Patients were
recruited between August 1999 and April 2013. FFPE
tissue was processed as detailed in Supplementary
materials and methods. All H&E slides were reviewed
by a single experienced liver histopathologist (JIW),
who identified clear examples to represent the range
of hepatocellular lesions, outlined the lesions on the
glass slides, and recorded their differentiation and
morphological pattern according to the World Health
Organisation (WHO) classification [21]; the annotated
H&E slides were then scanned using an automated
scanning system with a20 objective to produce dig-
ital images and uploaded to a digital pathology server:
https://bit.ly/31QugTa (supplementary material,
Table S2) [22]. DNA was extracted from the nodules
and from cirrhotic tissue geographically distant to
the nodules. HCC nodules (n = 106, including WD-
HCC n = 44) and DNs (n = 46, including high-grade
DNs, n = 28, and low-grade DNs, n = 18) were
retrieved from 59 patient livers.
• Validation cohort 2 – Blood-derived cell-free DNA
was obtained from 31 patients (HCC, n = 22, and cir-
rhosis without HCC, n = 9) from Nottingham, UK
with various aetiologies (Figure 1 and supplementary
material, Table S1 for clinico-pathological character-
istics). Patients were recruited between September
2016 and September 2017. HCC was diagnosed
radiologically according to European Association for
the Study of the Liver (EASL) criteria [23].
Sample processing
Detailed DNA extraction, library preparation, quality
control, sequencing, and bioinformatics methodology
can be found in Supplementary materials and methods
and Tables S3 and S4.
In brief, for validation cohort 1, test DNA was
extracted from FFPE dysplastic or malignant tissue.
Control DNA was extracted from the patient’s own cir-
rhotic tissue geographically distant to the nodule. Test
and control DNA were characterised in comparison to
a reference pool of normal DNA downloaded from the
1000 Genomes Project (see Supplementary materials
and methods) [24].
For validation cohort 2, test cell-free DNA was
extracted from the plasma of patients diagnosed with
HCC. Control cell-free DNA was extracted from the
plasma of patients diagnosed with liver cirrhosis and
found to be free of cancer on imaging for 6 months after
sample collection. Test and control samples were char-
acterised in comparison to the patient’s own buffy coat
genome.
The average coverage per genome was calculated by
multiplying the number of aligned reads by the read
length in base pairs, or double the read length if paired-
end, and dividing the result by 3 giga base pairs (supple-
mentary material, Table S3). We identified the predicted
proportion of tumour DNA within the eluted pool of
extracted DNA using ABSOLUTE (https://software.
broadinstitute.org/cancer/cga/absolute; supplementary
material, Table S5) [25]. The proportion of tumour
DNA within TCGA data was directly downloaded from
Genomics Data Commons (https://gdc.cancer.gov/
about-data/publications/pancanatlas) and can be found
in supplementary material, Table S6.
Plasma cell-free DNA sequencing
An 8.5-ml blood sample was obtained from each patient
and centrifuged within 2 h. The plasma and buffy coat
portions were extracted into different cryovials. Both
were re-centrifuged followed by re-extraction and stor-
age at80 C until further analysis. DNA concentration
was measured fluorometrically (PicoGreen®; Thermo
Fisher Scientific, Waltham, MA, USA) and fragmenta-
tion assessed using an Agilent 2200 TapeStation
(Agilent Technologies, Santa Clara, CA, USA). DNA
libraries were prepared using tagged primers as detailed
in Supplementary materials and methods and then
labelled using unique 6-bp tags to enable multiplexing
of libraries. Equal quantities of DNA libraries that
passed quality control were pooled for cluster amplifica-
tion and multiplexed on the same sequencing lane. Two
DNA library pools were prepared: a cell-free DNA sam-
ple pool and a reference sample pool. The cell-free DNA
sample pool included cell-free DNA samples from the
HCC (test) group and the liver cirrhosis (control) group.
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Ten nanograms of DNA library per sample was included
in the cell-free DNA pool and sequenced (Illumina
HiSeq3000; Illumina, San Diego, CA, USA) using
paired-end sequencing with a read length of 151 and
average coverage of 3–4x (IQR 2.8x–3.8x) per sample.
A description of the reference sample pool can be found
in Supplementary materials and methods.
FastQ files were output by the sequencer, two files per
sample, a file for each read. File integrity was verified
using MD5checksum and quality controlled using
FastQC (Babraham Institute, UK, https://www.
bioinformatics.babraham.ac.uk/projects/fastqc/). Adap-
tor sequences were trimmed using Cutadapt [26]. Nucle-
otide sequences were aligned against the human genome
assembly 19 (https://www.ncbi.nlm.nih.gov/assembly/
GCF_000001405.13/) using Burrows–Wheeler aligner
[27]. Sequences with poor mapping qualities less than
37 were not used. The number of aligned reads can be
found in supplementary material, Table S3. The aligned
reference read lengths were trimmed to match
aligned test read lengths. Each genome was divided into
100-kbp non-overlapping windows. The ratio of test to
reference number of reads per window was normalised
according to the most abundant ratio using CNAnorm
[28] (supplementary material, Figure S1), where the
most abundant ratio was considered as ratio 1 and
the other normalised ratios were calculated accordingly.
GC correction was performed using CNAnorm and
breakpoints were called using DNAcopy [29].
Detection and definition of arm-level somatic copy
number alterations
For the derivation cohort, copy number segment files
were downloaded from TCGA, https://gdc.cancer.gov/,
including the TCGA-LIHC cancer sub-cohort (n = 379)
and the TCGA-LIHC non-cancer sub-cohort (n = 305
blood-derived and 84 solid tissue).
For the validation cohorts, copy number segment files
were generated using CNAnorm [28]. Detailed bioinfor-
matics may be found in Supplementary materials and
methods. Centromeric locations were obtained from
the University of California Santa Cruz (UCSC) genome
browser and the mean value of normalised test to refer-
ence ratio for each autosomal arm was calculated (sup-
plementary material, Table S7).
Generation of thresholds using the TCGA-LIHC non-cancer
sub-cohort (n = 389)
Two thresholds were generated for each autosomal arm
to mark gains and losses. The thresholds were set at the
fifth and 95th centile values for losses and gains, respec-
tively (supplementary material, Table S8). Therefore,
less than 5% of the TCGA-LIHC non-cancer sub-cohort
exceeded the threshold for a gain or had values inferior
to the threshold for a loss.
Validation of thresholds using the TCGA threshold
validation sub-cohort (n = 7457)
The TCGA threshold validation sub-cohort comprised
non-cancer DNA sequences obtained from all TCGA
patients who had 26 different types of cancer (supple-
mentary material, Table S9). To investigate the potential
for false-positive results, the thresholds were tested
against copy number segment files of the TCGA thresh-
old validation sub-cohort (n = 7457).
Proportion of TCGA-HCC samples passing the threshold
The TCGA-LIHC cancer sub-cohort was used to iden-
tify the proportion of tumour samples passing the thresh-
old for each autosomal arm. Autosomal arms where the
proportion of tumour samples passing thresholds was
higher than 75% were identified. Figure 2 shows two
examples of autosomal arms where the proportions of
TCGA-HCC samples passing the threshold were higher
than 75%.
Statistical analyses
Cumulative frequency incorporates the frequency and
amplitude of autosomal arm alterations within a group
of lesions. This was used to display whole genome kar-
yotype for groups within both validation cohorts (sup-
plementary material, Figure S2).
To assess the capacity of key SCNAs identified using
the TCGA/derivation cohort in discriminating low- and
high-risk pathology, we analysed their prevalence within
each group and calculated the odds ratio (OR) with 95%
confidence interval (CI) according to Altman [30].
Results
Identification of key arm-level SCNAs
Key arm-level SCNAs were defined as those prevalent in
more than 75% of the TCGA-LIHC cancer sub-cohort.
This included 1q+ (90%), 4q (77%), 8p (76%), 8q+
(81%), and 17p (79%). Table 1 shows the prevalence
of 1q+, 4q, 8p, 8q+, and 17p within the study
groups explained in Figure 1.
Comparison of arm-level SCNAs in low- and
high-grade dysplastic nodules
To identify the potential for arm-level SCNAs in aiding
the discrimination of high-grade DNs from low-grade
DNs, the prevalence of key arm-level SCNAs within
both groups was examined. The likelihood of a dysplas-
tic nodule being high grade (n = 28) as opposed to low
grade (n = 18) in the presence or absence of 1q+,
4q, 8p, 8q+, and 17p was measured using the
OR. Development of high-grade dysplasia was associ-
ated with 1q+ OR = 8 (95% CI 1.5–41.5) and 8q+
OR = 5.8 (95% CI 1.4–24.5), as shown in Figure 3.
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Comparison of arm-level SCNAs in high-grade
dysplastic nodules and well-differentiated HCC
To identify the potential for arm-level SCNAs in aiding
the discrimination of well-differentiated HCC from
high-grade DNs, we examined the prevalence of key
arm-level SCNAs within both groups. The likelihood
of nodules being well-differentiated HCC (n = 44) as
opposed to high-grade DNs (n = 28) in the presence
or absence of 1q+, 4q, 8p, 8q+, and 17p was
measured using the OR. Development of early malig-
nant features was associated with 1q+ OR = 13.7
(95% CI 3.4–54.7), 4q OR = 3.8 (95% CI 1.4–
10.6), 8p OR = 5 (95% CI 1.6–15.7), and 8q+
OR = 4.9 (95% CI 1.5–13.7), as shown in Figure 3.
Comparison of 1q+ and 8q+ in low- and high-risk
pathology
We defined liver cirrhosis and low-grade dysplasia as
‘low-risk pathology’, while high-grade dysplasia and
cancer were defined as ‘high-risk pathology’. As 1q+
and 8q+ were detected in high-grade DNs significantly
more than in low-grade DNs, we aimed to explore their
utility for discriminating between ‘low-risk’ versus
Figure 2. Generation of thresholds. The TCGA-LIHC non-cancer sub-cohort (n = 305 blood-derived and 84 solid tissue) was used to generate
the thresholds which were set as the fifth and 95th centile values for each autosomal arm to mark losses and gains, respectively, in test sam-
ples. The TCGA-LIHC cancer sub-cohort (n = 379) included genomic sequencing of HCC. A shows the threshold for 17p set as 0.98 (fifth cen-
tile) of the TCGA-LIHC non-cancer sub-cohort and 79% of the TCGA-LIHC cancer sub-cohort had lower mean values for 17p. B shows the
threshold for 1q set as 1.01 (95th centile) of the TCGA-LIHC non-cancer sub-cohort and 90% of the TCGA-LIHC cancer sub-cohort had higher
mean values for 1q. Thresholds are marked using vertical black lines. Blue-shaded areas identify copy number losses and red-shaded areas
identify copy number gains.
Table 1. Prevalence of 1q+, 4q, 8p, 8q+, and 17p.
Group 1q+ 4q 8p 8q+ 17p
Derivation cohort (TCGA)
TCGA-LIHC cancer sub-cohort (n = 379) 340/379 (90%) 290/377 (77%) 285/377 (76%) 303/376 (81%) 271/343 (79%)
TCGA threshold validation sub-cohort (n = 7457) 445/7457 (6%) 396/7457 (5.3%) 226/7457 (3%) 404/7457 (5.4%) NA
Validation cohort 1 (FFPE)
HCC (n = 106) 95/106 (90%) 64/106 (60%) 59/106 (56%) 87/106 (82%) 53/106 (50%)
Well-differentiated HCC (n = 44) 41/44 (93%) 27/44 (61%) 23/44 (52%) 37/44 (84%) 22/44 (50%)
Moderately and poorly differentiated HCC
(n = 62)
54/62 (87%) 37/62 (60%) 36/62 (58%) 50/62 (81%) 31/62 (50%)
DNs (n = 46) 16/46 (35%) 13/46 (28%) 7/46 (15%) 18/46 (39%) 14/46 (30%)
Low-grade DNs (n = 18) 2/18 (11%) 2/18 (11%) 2/18 (11%) 3/18 (17%) 5/18 (28%)
High-grade DNs (n = 28) 14/28 (50%) 11/28 (39%) 5/28 (18%) 15/28 (54%) 9/28 (32%)
Liver cirrhosis (n = 32) 2/32 (6%) 8/32 (25%) 0/32 (0%) 4/32 (13%) 1/32 (3%)
Validation cohort 2 (blood-derived cell-free DNA)
HCC (n = 22) 19/22 (86%) 21/22 (96%) 15/22 (68%) 12/22 (55%) 7/22 (32%)
Cirrhosis (n = 9) 0/9 (0%) 4/9 (44%) 0/9 (0%) 0/9 (0%) 3/9 (33%)
DN, dysplastic nodule; FFPE, formalin-fixed, paraffin-embedded; HCC, hepatocellular carcinoma; TCGA-LIHC, The Cancer Genome Atlas – liver HCC.
Genomic characterisation of dysplastic liver nodules 5
© 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd.
on behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org
J Pathol 2021; 00: 000–000
www.thejournalofpathology.com
‘high-risk’ pathology. We therefore examined the preva-
lence of 1q+ and 8q+ within both groups. The odds of
pathology being ‘high risk’ (n = 134) as opposed to ‘low
risk’ (n = 50) in the presence or absence of 1q+ or 8q+
was measured using the OR. Development of ‘high-risk’
pathology was associated with 1q+ OR = 35.5 (95% CI
11.5–110) and 8q+ OR = 16 (95% CI 6.4–40.2).
Validation of thresholds using the TCGA threshold
validation sub-cohort (n = 7457)
To investigate the potential for false-positive results, the
thresholds were tested against non-cancer DNA
sequencing obtained from all TCGA patients who had
26 different types of cancer (n = 7457) but not liver can-
cer. In this cohort, the thresholds were crossed in
445 (6%) of 1q, 404 (5.4%) of 8q, 396 (5.3%) of 4q,
and 226 (3%) of 8p. None of the cases concurrently
crossed more than one of the four thresholds.
Arm-level SCNAs associated with early features of
malignancy are detectable using blood-derived cell-
free DNA
Cell-free DNA from the plasma and reference
DNA from the buffy coat of patients with HCC (test
group, n = 22) was compared with that from patients
with liver cirrhosis (control group, n = 9). The test
group included patients within Milan criteria (n = 7)
and patients with AFP < 20 ng/ml (n = 9) (Figure 4).
None of the patients recruited to the control group devel-
oped HCC after a median follow-up of 22.4 months.
Supplementary material, Table S10 shows the sensi-
tivity and specificity for each of the key arm-level
SCNAs. At least two or three of 1q+, 4q, 8p, and
8q+were present in 22/22 and 16/22 of the patients with
HCC, respectively (Figure 4). All patients in the control
group were negative for 1q+, 8p, and 8q+, while four
patients were positive for 4q. None of the control
group patients had more than one of the four arm-level
SCNAs. Such patterns were in close resemblance to
those observed in the TCGA threshold validation sub-
cohort and validation cohort 1 (Table 1 and Figure 5).
Discussion
The European Association for the Study of the Liver
(EASL) recommends the development of tools to stratify
patients at high, intermediate, and low risk for HCC [23].
In this study, we found that among five key arm-level
SCNAs in HCC, 1q+ and 8q+were significantly associ-
ated with either early cancer or high-grade dysplasia,
whereas such events were rare in low-grade dysplasia
or cirrhosis. We demonstrated that the alterations can
be detected using low-pass sequencing in blood-derived
cell-free DNA of patients with HCC but not cirrhotic
patients with no known HCC.
The detection on blood-derived cell-free DNA is
likely related to two factors. Firstly, the high prevalence
of arm-level SCNAs in HCC, TCGA data has revealed
that arm-level SCNAs are more prevalent than SCNAs
at gene level and more prevalent than common muta-
tions such as in TERT and CTNBB1 [10,31]. Secondly,
the natural signal amplification at duplication hotspots
such as 1q and 8q within a pool of cell-free DNA makes
the signal more detectable despite the low proportion of
circulating-tumour DNA. Cell-free DNA was directly
compared against buffy coat DNA from the same patient
as a reference, thus focusing on the cancer-related alter-
ations. Previous studies found variable concordance
between matching pairs of tumour and liquid biopsies,
as recently reviewed [32,33]. This was not the focus of
our study, which was on testing the utility of detecting
specific chromosomal arm-level SCNAs using low-pass
sequencing of cell-free DNA from patients with HCC.
The prevalence of such SCNAs in cell-free DNA may
be different to the tumour or the background liver tissue.
Similarly, area under receiver operating curve analysis
was not performed; the study was designed as a test of
feasibility and not designed for in-depth analysis, which
is the focus of currently ongoing work designed using
PRoBE (prospective specimen collection, retrospective
blind evaluation) [34].
There is variability in the literature regarding the opti-
mal method of identifying a true copy number event
[4,11,35]. The conventional z-score analysis is known
Figure 3. 1q+, 4q, 8q, and 8q+ can classify low-grade DNs,
high-grade DNs, and well-differentiated HCC. (A) Genomic struc-
tural features along the dysplasia–carcinoma axis in HCC. (B) Heat-
map showing gains (red) in 1q and 8q as well as losses (blue) in 4q,
8q, and 17p in low-grade DNs, high-grade DNs, and well-
differentiated HCC. HGDN, high-grade dysplastic nodules; LGDN,
low-grade dysplastic nodules; NS, not significant; WDHCC, well-
differentiated HCC.
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to be affected by the depth of sequencing, due to its reli-
ance on the standard deviation of the sequenced read
density from the reference group [11,36–38]. We have
generated fixed thresholds using TCGA sequencing data
of matched non-cancer tissue obtained from patients
diagnosed with HCC. The thresholds were validated on
three independent datasets (TCGA dataset, an FFPE
cohort, and a cell-free DNA cohort). More than 94% of
1q or 8q ratios obtained from non-cancer tissue
(n = 7457) were within a tight range between 0.997
and 1.013, and with similar patterns observed across
two independent datasets of patients with liver cirrhosis
and no cancer sequenced in-house (Table 1 and
Figure 5). This indicates a false-positive rate of less than
6% but much lower if both thresholds for 1q and 8q are
crossed as this was not observed in any of the DNA
Figure 4. Validation cohort 2: clinical characteristics of 22 patients with HCC and prevalence of 1q+, 4q, 8p, and 8q+ using blood-
derived cell-free DNA. (A) AFP < 20 ng/ml; (B) AFP 20–200 ng/ml. (C) AFP > 200 ng/ml. AFP, alpha-fetoprotein; CPS, Child–Pugh score;
PVT, portal venous thrombosis; SCNAs, somatic copy number alterations.
Figure 5. 1q+, 4q, 8p, and 8q+ are common in HCC and uncommon in cirrhosis. Similar patterns are observed in tissue DNA and blood-
derived cell-free DNA. C, cirrhosis; HCC, hepatocellular carcinoma.
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tested across three independent control cohorts. On the
other hand, either 1q or 8q threshold was crossed in
104/106 HCCs in validation cohort 1 and in 20/22 HCCs
in validation cohort 2, while both 1q and 8q thresholds
were crossed in 78/106 HCCs in validation cohort
1 and in 11/22 HCCs in validation cohort 2, which indi-
cates a potentially satisfactory negative predictive value
(supplementary material, Tables S7 and S8). The thresh-
olds are easily reproducible, unaffected by the depth of
sequencing, and external validation highlights the poten-
tial for promising accuracy (supplementary material,
Table S9).
A landmark study from Hong Kong investigating
patients with hepatitis B virus found clear evidence of
SCNAs in plasma DNA of 84.4% of patients who had
HCC and 22.2% of patients with cirrhosis [11]. Our
study showed similar results (Table 1) for patients with
diverse background aetiologies and using low-pass
sequencing. Our study agrees with deep sequencing
studies and SNP arrays reporting the common copy
number features in HCC as shown in supplementary
material, Figure S2 [10–12,14,39]. Two earlier studies
investigating gene transcriptional profiles have proposed
molecular markers targeted at discriminating stages of
hepatocarcinogenesis. This included dysplastic nodules
and early HCC. However, in both studies, most of the
dysplastic nodules included were low-grade DNs
(n = 10/16). Therefore, it is not clear if the same signa-
tures would discriminate between high-grade DNs and
early HCC [40,41]. The rate of HCC development is sig-
nificantly higher in high-grade DNs than in low-grade
DNs and regenerative nodules [8]. Moreover, an interna-
tional consensus panel did not find difficulty in differen-
tiating between low-grade DNs and early HCC. The
diagnostic discrepancy arose in the discrimination of
low-grade DNs from high-grade DNs and of high-grade
DNs from well-differentiated HCC [1]. Our study
included a considerable number of high-grade DNs
(n = 28) aiming to address this issue. Previous studies
identified the increase in chromosomal instability from
DNs to HCC [3,5]. More recently, Torrecilla et al [4]
reported copy number data on low-grade DNs
(n = 14), high-grade DNs (n = 15), and small HCC
(n = 17) and identified 1q+, 8q+, and 8q as potential
‘gate-keeper’ events, due to their prevalence in dysplas-
tic nodules. Our work agreed, characterising 1q+, 8p,
and 8q+, as well as 4q and 17p, as early events in
hepatocarcinogenesis.
EASL clinical practice guidelines currently recom-
mend biopsy for liver nodules larger than 1 cm that do
not show typical HCC features on at least one out of
two imaging modalities [23]. The American Association
for the Study of Liver Diseases (AASLD) endorses the
Liver Imaging Reporting And Data System (LI-RADS)
and recommends biopsy for lesions classed as ‘probably
HCC (LR-4)’ or ‘malignant but not HCC (LR-M)’ [42].
Histopathologists face inherent difficulties in discrimi-
nating between high-grade DNs and well-differentiated
HCC [43,44]. EASL recommends the use of a panel of
three immunohistochemistry (IHC) antibodies to aid
the histological discrimination of high-grade DNs from
well-differentiated HCC [23]. However, a recent collab-
oration of Eastern and Western expert pathologists vali-
dating the EASL recommended panel found a sensitivity
of 52% and recommended two further IHC antibodies to
raise the sensitivity to 93%, suggesting that this may be
difficult to apply in routine clinical practice [9]. Our
study showed that 1q+ and 8q+were significantly more
prevalent in high-grade DNs than in low-grade DNs. 1q
+, 4q, 8p, and 8q+ were significantly more preva-
lent in well-differentiated HCC than in high-grade
DNs. Our study suggests that identification of arm-level
SCNAs (1q+, 4q, 8p, and 8q+) has the potential to
improve the current inter-observer agreement on tissue
histopathological distinction between high-grade DNs
and well-differentiated HCC [1,9].
Our study made an attempt to characterise low-grade
DNs, high-grade DNs, and well-differentiated HCC
according to their broad chromosomal structure. The
detection of such chromosomal features is technically
simple and applicable in day-to-day clinical practise.
For instance, cytogenetic analysis of BCR/ABL1 translo-
cation, HER2 amplification, and ALK rearrangement is
the current standard of care for guiding the management
of chronic myeloid leukaemia [45], breast cancer [46],
and lung adenocarcinoma [47], respectively. Unlike
pre-malignant lesions in other cancers such as Barrett’s
oesophagus [48] and colonic polyps [49], high-grade
dysplasia in HCC currently is treated similarly to any
other ‘low-risk’ lesion, such as regenerative nodules.
This could be related partially to the difficulty in identi-
fying and discriminating different stages of pre-
malignant hepatic nodules. With rising indications for
targeted liver biopsy, and known histopathological chal-
lenges even amongst experts, incorporating cytogenetic
examinations for 1q+ and 8q+may providemore objec-
tive discrimination even for non-expert pathologists.
Moreover, liquid biopsy is a future non-invasive tool
as such features can be detectable using low-pass
sequencing (3–4x coverage). This is significantly less
costly and less time-consuming in comparison to deep
sequencing, which is not required for the purpose of
detection of key arm-level SCNAs. Low-pass sequenc-
ing is still likely to be superior to alternative techniques
as it enables delicate discrimination of ratios between
0.99 and 1.01 using small quantities of starting DNA.
Our study had some limitations; most dysplastic nod-
ules (n = 42/46) were extracted from livers that har-
boured HCC as well, and the results may be different
in livers harbouring DNs without HCC. Conversely,
such livers may or may not ever develop cancer and fur-
ther longitudinal studies on the natural history of DNs
are required to identify the most appropriate DNs for
study of genomic predictors of malignant transforma-
tion. Torrecilla et al recently found significantly lower
prevalence of arm-level SCNAs in DNs that were
retrieved from cirrhotic livers that did not have cancer.
The lower prevalence reported by Torrecilla et al may
be related to the biology of such DNs or higher thresh-
olds for calling SCNAs [4]. Moreover, a recent study
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based on phylogenetic analysis of single nucleotide var-
iants and copy number profiles found evidence of inde-
pendent growth of DNs and HCC within the same
patient liver [50]. The majority, but not all (n = 34/44),
of well-differentiated HCCs in validation cohort 1 were
small (i.e. ≤2 cm; IQR = 11–21 mm). Our study was
designed to discriminate histopathological features
rather than nodule size. Our patient group in validation
cohort 2 included generally more advanced cancers
(only seven out of 22 were within Milan criteria, two
of whom had liver transplantation and five were consid-
ered for transplants). Further work is required to deter-
mine whether early HCC which has less vascular
invasion, or indeed dysplastic nodules, also releases
cell-free DNA with detectable arm-level SCNAs into
the peripheral circulation. Lastly, validation cohort
1 was all related to HCV, with a question about the gen-
eralisability, but the findings had no obvious correlation
with aetiology in the cell-free DNA dataset.
In conclusion, 1q+ or 8q+ is associated with high-
risk liver pathology, e.g. cancer or high-grade dysplasia,
but not low-risk pathology, e.g. low-grade dysplasia and
liver cirrhosis. Detection of 1q+, 4q, 8p, and 8q+ in
the tissue may aid in distinguishing types of liver nod-
ules and in subsequent decision making. Arm-level
SCNAs can be detected in blood-derived cell-free
DNA using low-pass sequencing, which may be useful
as a tool for the surveillance, diagnosis, and monitoring
of HCC in patients with cirrhosis.
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